source
- FDA approves Scholar Rock's muscle-targeted SMA therapy IsembyldThe Food and Drug Administration has approved a new medication for spinal muscular atrophy (SMA). The drug, apitegromab marketed as Isembyld, is the first muscle-targeted therapy for the disease.…
- Karyopharm Secures One-Month Debt Extension While Awaiting Xpovio DecisionKaryopharm Therapeutics, facing cash constraints, has negotiated a temporary reprieve on a $15.8 million debt that was due. Under the agreement, lenders and noteholders will refrain from enforceme…